Dr. Samson Darrah, an alumnus of the College of Science at the Kwame Nkrumah University of Science and Technology (KNUST), Kumasi has been awarded the David R. Pepperberg Memorial Travel Grant in recognition of his contributions to advancing vision science research.
The grant supports promising researchers to participate in the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). It is named in honor of David R. Pepperberg, a respected scientist known for his work on phototransduction.
The award recognizes individuals who demonstrate strong potential to contribute to innovation and collaboration in vision research.
Dr. Darrah is a PhD student in Bioengineering at the University of Washington in the United States. He was featured in a news release at the 2026 ARVO Annual Meeting, one of the world’s leading gatherings of researchers in eye and vision science.
His research focuses on understanding genotype–phenotype relationships in retinal anomalies (including retinitis pigmentosa) using advanced ophthalmic imaging techniques and long-read genetic sequencing.
Retinitis pigmentosa is a group of inherited conditions that lead to progressive degeneration of photoreceptor cells, resulting in gradual vision loss. The disease affects millions worldwide and remains a major cause of inherited blindness, with no universal cure currently available.
At the 2026 ARVO Annual Meeting, Dr. Darrah presented findings from an ancillary imaging study within the N-acetylcysteine (NAC) Attack phase III clinical trial, an international, multicenter study investigating whether N-acetylcysteine can slow the progression of vision loss in patients with retinitis pigmentosa.
His work used optoretinography (ORG), a non-invasive imaging technique that measures how photoreceptors respond to light, to establish a functional baseline in participants before treatment.
The study showed that retinal function can be significantly reduced even in areas where retinal structure appears preserved, highlighting a gap that conventional imaging methods may not detect.
These findings suggest that optoretinography could serve as a sensitive biomarker for detecting early functional decline and for monitoring treatment response in clinical trials.
This has the potential to improve how new therapies are evaluated and may help accelerate the development of effective treatments for retinal diseases.
Dr. Darrah’s long-term goal is to translate advances in retinal imaging and genetics into tools that can improve patient care, enable earlier diagnosis, and guide the development of more effective therapies.
His recognition reflects the growing impact of KNUST-trained scientists on the global research space and highlights the university’s commitment to producing graduates who contribute meaningfully to scientific advancement and the solution of critical health challenges.
